Health Care • Biotechnology: Pharmaceutical Preparations
$51.45 ▲ +0.71
(+1.40%)
MKT CAP: $961.1M • VOL: 159.6K
52W L $25 52W H $53
RIGL // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $294.3M | $179.3M | $116.9M |
| YoY Revenue Growth % | +64.1% | +53.4% | — |
| Gross Profit | $274.7M | $160.6M | — |
| Gross Margin % | 93.3% | 89.6% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $125.5M | $24.2M | -$20.5M |
| Operating Margin % | 42.6% | 13.5% | -17.5% |
| Net Income (GAAP) | $367.0M | $17.5M | -$25.1M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $75.7M | $31.5M | -$5.7M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | $75.7M | $31.5M | -$5.7M |
| FCF Margin % | 25.7% | 17.6% | -4.9% |
| Return on Invested Capital (ROIC %) | 28.2% | 95.0% | — |
| Cash & Short-Term Equivalents | $40.6M | $56.7M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $391.5M | $3.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR RIGL.